PTPRC and neoplasm: Flt3L‐based immunotherapy has the potential to enhance the oligoclonal expansion of host T cells and to promote the infiltration of tumors by antigen‐specific endogenous T cells (host‐derived and not exogenously adoptively transferred).[60] Consequently, to ascertain whether combined treatment can amplify endogenous TTSM cells, we performed single‐cell RNA sequencing (scRNA‐seq) on CD45+CD19−Ly6G− cells sorted from TdLN in LLC tumor rechallenge murine model via the 10× Genomics platform and ultimately identified nine distinct cell populations (Figure S2A, Supporting Information).